Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 595

1.

Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.

Chang YT, Hernandez D, Alonso S, Gao M, Su M, Ghiaur G, Levis MJ, Jones RJ.

Blood Adv. 2019 Mar 26;3(6):908-916. doi: 10.1182/bloodadvances.2018022921.

2.

Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

Bolaños-Meade J, Cooke KR, Gamper CJ, Ali SA, Ambinder RF, Borrello IM, Fuchs EJ, Gladstone DE, Gocke CB, Huff CA, Luznik L, Swinnen LJ, Symons HJ, Terezakis SA, Wagner-Johnston N, Jones RJ, Brodsky RA.

Lancet Haematol. 2019 Mar 13. pii: S2352-3026(19)30031-6. doi: 10.1016/S2352-3026(19)30031-6. [Epub ahead of print]

PMID:
30878319
3.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.

PMID:
30824040
4.

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.

Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZ.

Blood. 2019 Feb 8. pii: blood-2018-06-859686. doi: 10.1182/blood-2018-06-859686. [Epub ahead of print]

PMID:
30737236
5.

R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.

Messmer M, Tsai HL, Varadhan R, Swinnen LJ, Jones RJ, Ambinder RF, Shanbhag SP, Borowitz MJ, Wagner-Johnston N.

Leuk Lymphoma. 2019 Jan 18:1-5. doi: 10.1080/10428194.2018.1519812. [Epub ahead of print]

PMID:
30656983
6.

Reactor design and integration with product detection to accelerate screening of electrocatalysts for carbon dioxide reduction.

Jones RJR, Wang Y, Lai Y, Shinde A, Gregoire JM.

Rev Sci Instrum. 2018 Dec;89(12):124102. doi: 10.1063/1.5049704.

PMID:
30599585
7.

Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, Bolaños-Meade J, Borrello I, Matsui WH, Swinnen LJ, Huff CA, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2018 Dec 30. pii: S1083-8791(18)31700-2. doi: 10.1016/j.bbmt.2018.12.767. [Epub ahead of print]

PMID:
30599208
8.

3D Molecular Cytology of Hop (Humulus lupulus) Meiotic Chromosomes Reveals Non-disomic Pairing and Segregation, Aneuploidy, and Genomic Structural Variation.

Easterling KA, Pitra NJ, Jones RJ, Lopes LG, Aquino JR, Zhang D, Matthews PD, Bass HW.

Front Plant Sci. 2018 Nov 1;9:1501. doi: 10.3389/fpls.2018.01501. eCollection 2018.

9.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.

Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.

10.

Sediment characteristics influence the fertilisation success of the corals Acropora tenuis and Acropora millepora.

Ricardo GF, Jones RJ, Clode PL, Humanes A, Giofre N, Negri AP.

Mar Pollut Bull. 2018 Oct;135:941-953. doi: 10.1016/j.marpolbul.2018.08.001. Epub 2018 Aug 16.

11.

Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.

Dobbin SJH, Cameron AC, Petrie MC, Jones RJ, Touyz RM, Lang NN.

Heart. 2018 Dec;104(24):1995-2002. doi: 10.1136/heartjnl-2018-313726. Epub 2018 Sep 18. Review.

PMID:
30228246
12.

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.

Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, Fuchs EJ, Levis M, Ambinder RF, Jones RJ, Gladstone DE.

Blood Adv. 2018 Sep 11;2(17):2226-2229. doi: 10.1182/bloodadvances.2018019208.

13.

Should an HLA-matched donor still be considered the perfect donor?

Jones RJ, Horowitz MM.

Lancet Haematol. 2018 Sep;5(9):e388-e390. doi: 10.1016/S2352-3026(18)30119-4. No abstract available.

PMID:
30172342
14.

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.

Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ.

Clin Cancer Res. 2018 Dec 15;24(24):6408-6420. doi: 10.1158/1078-0432.CCR-17-3265. Epub 2018 Aug 20.

PMID:
30126942
15.

Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment.

DeZern AE, Jones RJ, Brodsky RA.

Biol Blood Marrow Transplant. 2018 Dec;24(12):e26-e30. doi: 10.1016/j.bbmt.2018.07.032. Epub 2018 Jul 26.

PMID:
30055352
16.

Clinical skills of a new foundation dentist: the experience of dental foundation educational supervisors.

Jones RJ, Cowpe JG, Bullock AD, Gilmour ASM.

Br Dent J. 2018 Jul 27;225(2):177-186. doi: 10.1038/sj.bdj.2018.536. No abstract available.

PMID:
30050194
17.

Clinical skills of a new foundation dentist: the expectations of dental foundation education supervisors.

Gilmour ASM, Jones RJ, Cowpe JG, Bullock AD.

Br Dent J. 2018 Jul 13;225(1):73-80. doi: 10.1038/sj.bdj.2018.526. Epub 2018 Jul 6. No abstract available.

PMID:
29977021
18.

Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.

McCurdy SR, Muth ST, Tsai HL, Symons HJ, Huff CA, Matsui WH, Borrello I, Gladstone DE, Swinnen LJ, Cooke KR, Brodsky RA, Bolaños-Meade J, Ambinder RF, Varadhan R, Luznik L, Jones RJ, Bettinot MP, Fuchs EJ.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2056-2064. doi: 10.1016/j.bbmt.2018.06.004. Epub 2018 Jun 15.

19.

Corrigendum to "Settlement patterns of the coral Acropora millepora on sediment-laden surfaces" [Sci. Total Environ. 609 (2017) 277-288].

Ricardo GF, Jones RJ, Nordborg M, Negri AP.

Sci Total Environ. 2018 Nov 1;640-641:116. doi: 10.1016/j.scitotenv.2018.05.219. Epub 2018 May 30. No abstract available.

PMID:
29859428
20.

Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.

Jones RJ.

Oncology (Williston Park). 2018 May 15;32(5):223, 226-7, 247. No abstract available.

21.

Extending surgeon response times in tier 2 traumas does not adversely affect patient outcomes.

Zimmerman SA, Reed CS, Reed AN, Jones RJ, Chard A, Reed DN Jr.

J Surg Res. 2018 Jun;226:24-30. doi: 10.1016/j.jss.2017.12.037. Epub 2018 Feb 10.

PMID:
29661285
22.

Dual-comb spectroscopy of laser-induced plasmas.

Bergevin J, Wu TH, Yeak J, Brumfield BE, Harilal SS, Phillips MC, Jones RJ.

Nat Commun. 2018 Mar 28;9(1):1273. doi: 10.1038/s41467-018-03703-0.

23.

Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.

Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ.

Leukemia. 2018 Oct;32(10):2224-2239. doi: 10.1038/s41375-018-0044-x. Epub 2018 Mar 27.

24.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2018 May;24(5):1099-1102. doi: 10.1016/j.bbmt.2018.02.005. Epub 2018 Feb 13.

PMID:
29452245
25.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, Huff CA, Swinnen LJ, Brodsky RA, Matsui WH, Borrello I, Shanbhag S, Cooke KR, Ambinder RF, Luznik L, Bolaños-Meade J, Jones RJ.

Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.

26.

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.

Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, Flowers MED, Giralt S, Horowitz MM, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1274-1280. doi: 10.1016/j.bbmt.2018.01.002. Epub 2018 Jan 8.

PMID:
29325830
27.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.

28.

Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.

Schoch LK, Asiama A, Zahurak M, Shanbhag S, Hurtt J, Sawyer K, Swinnen LJ, Wagner-Johnston N, Jones RJ, Ambinder RF, Gladstone DE.

Cancer Chemother Pharmacol. 2018 Feb;81(2):347-354. doi: 10.1007/s00280-017-3499-y. Epub 2017 Dec 13.

PMID:
29234922
29.

Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes.

Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZ.

Oncotarget. 2017 Aug 27;8(43):73723-73732. doi: 10.18632/oncotarget.20564. eCollection 2017 Sep 26.

30.

Immune checkpoint inhibitors in renal cell carcinoma.

Ross K, Jones RJ.

Clin Sci (Lond). 2017 Oct 27;131(21):2627-2642. doi: 10.1042/CS20160894. Print 2017 Nov 1. Review.

31.

Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, Huff CA, Borrello I, Matsui WH, Brodsky RA, Ambinder RF, Bettinotti MP, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2018 Feb;24(2):343-352. doi: 10.1016/j.bbmt.2017.10.023. Epub 2017 Oct 18.

32.

Y-Chromosome haplotypes reveal relationships between populations of the Arabian Peninsula, North Africa and South Asia.

Jones RJ, Tay GK, Mawart A, Alsafar H.

Ann Hum Biol. 2017 Dec;44(8):738-746. doi: 10.1080/03014460.2017.1384508. Epub 2017 Oct 16.

PMID:
28948851
33.

Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.

Rulach RJ, McKay S, Neilson S, White L, Wallace J, Carruthers R, Lamb C, Cascales A, Marashi H, Glen H, Venugopal B, Sadoyze A, Sidek N, Russell JM, Alhasso A, Dodds D, Laskey J, Jones RJ, MacLeod N.

BJU Int. 2018 Feb;121(2):268-274. doi: 10.1111/bju.14025. Epub 2017 Oct 15.

34.

Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Bruner JK, Ma HS, Li L, Qin ACR, Rudek MA, Jones RJ, Levis MJ, Pratz KW, Pratilas CA, Small D.

Cancer Res. 2017 Oct 15;77(20):5554-5563. doi: 10.1158/0008-5472.CAN-16-2593. Epub 2017 Sep 18.

35.

Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia.

Pallavajjala A, Kim D, Li T, Ghiaur G, Jones RJ, Burns KH, Salzberg SL, Ning Y.

Leuk Lymphoma. 2018 May;59(5):1231-1238. doi: 10.1080/10428194.2017.1372577. Epub 2017 Sep 7.

36.

Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Llosa NJ, Cooke KR, Chen AR, Gamper CJ, Klein OR, Zambidis ET, Luber B, Rosner G, Siegel N, Holuba MJ, Robey N, Hayashi M, Jones RJ, Fuchs E, Holdhoff M, Loeb DM, Symons HJ.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2127-2136. doi: 10.1016/j.bbmt.2017.08.012. Epub 2017 Aug 12.

37.

Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.

Imus PH, Blackford AL, Bettinotti M, Iglehart B, Dietrich A, Tucker N, Symons H, Cooke KR, Luznik L, Fuchs EJ, Brodsky RA, Matsui WH, Huff CA, Gladstone D, Ambinder RF, Borrello IM, Swinnen LJ, Jones RJ, Bolaños-Meade J.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1887-1894. doi: 10.1016/j.bbmt.2017.07.014. Epub 2017 Jul 25.

38.

Retinoic acid, CYP26, and drug resistance in the stem cell niche.

Alonso S, Jones RJ, Ghiaur G.

Exp Hematol. 2017 Oct;54:17-25. doi: 10.1016/j.exphem.2017.07.004. Epub 2017 Jul 25. Review.

39.

Settlement patterns of the coral Acropora millepora on sediment-laden surfaces.

Ricardo GF, Jones RJ, Nordborg M, Negri AP.

Sci Total Environ. 2017 Dec 31;609:277-288. doi: 10.1016/j.scitotenv.2017.07.153. Epub 2017 Jul 24. Erratum in: Sci Total Environ. 2018 Nov 1;640-641:116.

40.

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.

Ghosh N, Ye X, Tsai HL, Bolaños-Meade J, Fuchs EJ, Luznik L, Swinnen LJ, Gladstone DE, Ambinder RF, Varadhan R, Shanbhag S, Brodsky RA, Borrello IM, Jones RJ, Matsui W, Huff CA.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1903-1909. doi: 10.1016/j.bbmt.2017.07.003. Epub 2017 Jul 12.

41.

Developing transcriptional profiles in Orbicella franksi exposed to copper: Characterizing responses associated with a spectrum of laboratory-controlled environmental conditions.

Morgan MB, Edge SE, Venn AA, Jones RJ.

Aquat Toxicol. 2017 Aug;189:60-76. doi: 10.1016/j.aquatox.2017.05.005. Epub 2017 May 12. No abstract available.

PMID:
28599170
42.

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators.

N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900. Epub 2017 Jun 3.

43.

Haplotype Counting for Sensitive Chimerism Testing: Potential for Early Leukemia Relapse Detection.

Debeljak M, Mocci E, Morrison MC, Pallavajjalla A, Beierl K, Amiel M, Noë M, Wood LD, Lin MT, Gocke CD, Klein AP, Fuchs EJ, Jones RJ, Eshleman JR.

J Mol Diagn. 2017 May;19(3):427-436. doi: 10.1016/j.jmoldx.2017.01.005.

44.

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.

Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A, Stockdale A, Sundar S, Crabb SJ, Dixon-Hughes J, Alexander L, Morris A, Kelly C, Stobo J, Paul J, Powles T.

J Clin Oncol. 2017 Jun 1;35(16):1770-1777. doi: 10.1200/JCO.2016.70.7828. Epub 2017 Apr 12.

PMID:
28402747
45.

RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.

Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, Kuiatse I, Gu D, Wang Z, Ma W, Lim J, O'Brien S, Keats J, Yang J, Davis RE, Orlowski RZ.

Br J Haematol. 2017 Apr;177(1):80-94. doi: 10.1111/bjh.14525.

46.

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, Attard G, Cross W, Jones RJ, Parker CC, Russell JM, Thalmann GN, Schiavone F, Cassoly E, Matheson D, Millman R, Rentsch CA, Barber J, Gilson C, Ibrahim A, Logue J, Lydon A, Nikapota AD, O'Sullivan JM, Porfiri E, Protheroe A, Srihari NN, Tsang D, Wagstaff J, Wallace J, Walmsley C, Parmar MKB, Sydes MR; STAMPEDE Investigators.

J Clin Oncol. 2017 May 10;35(14):1530-1541. doi: 10.1200/JCO.2016.69.0677. Epub 2017 Mar 13.

47.

Population data for 21 autosomal short tandem repeat markers in the Arabic population of the United Arab Emirates.

Jones RJ, Tayyare WA, Tay GK, Alsafar H, Goodwin WH.

Forensic Sci Int Genet. 2017 May;28:e41-e42. doi: 10.1016/j.fsigen.2017.02.015. Epub 2017 Mar 1. No abstract available.

PMID:
28291711
48.

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.

Crabb SJ, Birtle AJ, Martin K, Downs N, Ratcliffe I, Maishman T, Ellis M, Griffiths G, Thompson S, Ksiazek L, Khoo V, Jones RJ.

Invest New Drugs. 2017 Oct;35(5):599-607. doi: 10.1007/s10637-017-0433-4. Epub 2017 Feb 1.

49.

Increased biohydrogen yields, volatile fatty acid production and substrate utilisation rates via the electrodialysis of a continually fed sucrose fermenter.

Jones RJ, Massanet-Nicolau J, Mulder MJ, Premier G, Dinsdale R, Guwy A.

Bioresour Technol. 2017 Apr;229:46-52. doi: 10.1016/j.biortech.2017.01.015. Epub 2017 Jan 11.

PMID:
28107721
50.

Gastight Hydrodynamic Electrochemistry: Design for a Hermetically Sealed Rotating Disk Electrode Cell.

Jung S, Kortlever R, Jones RJ, Lichterman MF, Agapie T, McCrory CC, Peters JC.

Anal Chem. 2017 Jan 3;89(1):581-585. doi: 10.1021/acs.analchem.6b04228. Epub 2016 Dec 19.

PMID:
28105829

Supplemental Content

Loading ...
Support Center